“Some of the early data that came out of the [ECHO] trial that led to this approval does suggest that it may be beneficial in some high-risk patients,” Tycel Phillips, MD, said.
Approval Alert | Acalabrutinib Plus Bendamustine/Rituximab in Previously Untreated MCL
The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
mRNA Vaccine/Pembrolizumab Shows Sustained 5-Year RFS in High-Risk Melanoma
2
FDA Grants Breakthrough Therapy Designation to Sofetabart Mipitecan in PROC
3
FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer
4
Zevor-Cel Shows Long-Term Efficacy in Small R/R Multiple Myeloma Population
5